Logo

American Heart Association

  38
  0


Final ID:

Risky Business (PRO): Can Immunotherapy Be an Opportunity in Heart Transplant Patients?

  • Yang, Eric  ( UCLA MEDICAL CENTER , Culver City , California , United States )
  • Kamath, Megan  ( UCLA , Los Angeles , California , United States )
  • Srivastava, Pratyaksh  ( UCLA Ronald Reagan Medical Center , Los Angeles , California , United States )
  • Author Disclosures:
    Eric Yang: DO have relevant financial relationships ; Researcher:CSL Behring:Past (completed) ; Speaker:Zoll Medical:Active (exists now) ; Speaker:National Comprehensive Cancer Network:Past (completed) ; Consultant:Xencor:Past (completed) ; Consultant:Edwards Lifesciences:Active (exists now) ; Researcher:Janssen Research and Development:Active (exists now) ; Researcher:Bristol Myers Squibb:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Researcher:Boehringer Ingelheim and Eli and Lilly Company:Past (completed) | Megan Kamath: No Answer | Pratyaksh Srivastava: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Viral Controversies in Heart Failure, Cardiomyopathy, and Cardio-Oncology

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Risky Business (CON): Can Immunotherapy Be Outlawed in Heart Transplant Patients?

Cheng Richard, Vucicevic Darko, Shahandeh Negeen, Kopecky Benjamin

Ironing Out Infection Risk (CON): IV Iron is More Help Than Harm

Beavers Craig, Gale Stormi, Bagnola Aaron, Mcilvennan Colleen, Peters Laura

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available